Literature DB >> 17069579

An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura.

Spero R Cataland1, Ming Jin, Amy K Ferketich, Melanie S Kennedy, Eric H Kraut, James N George, Haifeng M Wu.   

Abstract

We present the results of two consecutively performed cohort studies that evaluated the clinical effects of corticosteroids or cyclosporin as an adjunct to plasma exchange (PE) for the treatment of an acute episode of thrombotic thrombocytopenic purpura (TTP). In comparing 12 corticosteroid-treated patients with eight cyclosporin-treated patients, none of the cyclosporin-treated patients suffered an exacerbation or recurrence of TTP in the first 30 d after discontinuing PE compared with 6/10 (60%) of the corticosteroid-treated patients (P = 0.042). These data suggest that cyclosporin may have advantages over corticosteroids as an adjunct to PE therapy in the initial treatment of idiopathic TTP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17069579     DOI: 10.1111/j.1365-2141.2006.06384.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  19 in total

Review 1.  Thrombotic thrombocytopenic purpura: recognition and management.

Authors:  Joseph E Kiss
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

2.  ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model.

Authors:  Eric M Ostertag; Khalil Bdeir; Stephen Kacir; Michelle Thiboutot; Gayathri Gulendran; Lenka Yunk; Vincent M Hayes; David G Motto; Mortimer Poncz; X Long Zheng; Douglas B Cines; Don L Siegel
Journal:  Transfusion       Date:  2016-04-04       Impact factor: 3.157

3.  ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro.

Authors:  Eric M Ostertag; Stephen Kacir; Michelle Thiboutot; Gayathri Gulendran; X Long Zheng; Douglas B Cines; Don L Siegel
Journal:  Transfusion       Date:  2016-04-04       Impact factor: 3.157

4.  Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura.

Authors:  Spero R Cataland; Peter J Kourlas; Shangbin Yang; Susan Geyer; Leslie Witkoff; Haiwa Wu; Camila Masias; James N George; Haifeng M Wu
Journal:  Blood Adv       Date:  2017-10-23

5.  Cyclosporin A impairs the secretion and activity of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat).

Authors:  Klilah Hershko; Vijaya L Simhadri; Adam Blaisdell; Ryan C Hunt; Jordan Newell; Sandra C Tseng; Alon Y Hershko; Jae Won Choi; Zuben E Sauna; Andrew Wu; Richard J Bram; Anton A Komar; Chava Kimchi-Sarfaty
Journal:  J Biol Chem       Date:  2012-11-09       Impact factor: 5.157

6.  Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura.

Authors:  Hanny Al-Samkari; Rachael F Grace; Jean M Connors
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

Review 7.  Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis.

Authors:  Nay M Tun; Gina M Villani
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

8.  Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.

Authors:  Spero R Cataland; Ming Jin; Shili Lin; Eric H Kraut; James N George; Haifeng M Wu
Journal:  Am J Hematol       Date:  2008-12       Impact factor: 10.047

9.  Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

10.  ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.